Cargando…

Expression of laminin-1 and matrix metalloproteinase-9 in benign and malignant endometrium

BACKGROUND/AIM: Laminin-1 and matrix metalloproteinase (MMP)-9 may play roles in the progression from benign to malignant endometrium, so we aimed to investigate their levels of expression in these tissues. MATERIALS AND METHODS: This case-control study was conducted at a tertiary care center betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: KÜÇÜKAYDIN, Zehra, BAŞARAN, Mustafa, ÜNLÜ, Yaşar, BAŞARAN, Ahmet, KURDOĞLU, Mertihan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientific and Technological Research Council of Turkey (TUBITAK) 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388054/
https://www.ncbi.nlm.nih.gov/pubmed/36945954
http://dx.doi.org/10.55730/1300-0144.5568
_version_ 1785082024738947072
author KÜÇÜKAYDIN, Zehra
BAŞARAN, Mustafa
ÜNLÜ, Yaşar
BAŞARAN, Ahmet
KURDOĞLU, Mertihan
author_facet KÜÇÜKAYDIN, Zehra
BAŞARAN, Mustafa
ÜNLÜ, Yaşar
BAŞARAN, Ahmet
KURDOĞLU, Mertihan
author_sort KÜÇÜKAYDIN, Zehra
collection PubMed
description BACKGROUND/AIM: Laminin-1 and matrix metalloproteinase (MMP)-9 may play roles in the progression from benign to malignant endometrium, so we aimed to investigate their levels of expression in these tissues. MATERIALS AND METHODS: This case-control study was conducted at a tertiary care center between January 2014 and December 2016. Paraffin blocks of 50 specimens of benign endometrium with proliferative (n = 20), secretory (n = 11), and atrophic (n = 5) endometrium; simple endometrial hyperplasia without atypia (n = 12); and endometrial polyp (n = 2) histology and 49 specimens of malignant endometrium with endometrioid (n = 40), serous (n = 7), clear cell (n = 1), and undifferentiated (n = 1) types were immunostained with laminin-1 and MMP-9 antibodies and assessed for basement membrane continuity for laminin-1 and the percentage and intensity of MMP-9 expression in epithelial cytoplasm. RESULTS: Laminin-1 continuity in the basement membrane was higher in benign (92%) compared to malignant (16.3%) endometrium (p < 0.0001) without any difference between the subgroups within each group (p > 0.05). All atrophic endometria and endometrial polyps and 23.5% of low grade endometrioid and none of the other endometrial cancers showed uninterrupted basement membrane staining with laminin-1. All cases in malignant endometrium expressed MMP-9 with either low or high immunoreactivity while none of the cases in benign endometrium showed a high staining with MMP-9 (p < 0.01). Proliferative and hyperplastic endometrium together with grade 1 endometrioid cancer expressed MMP-9 better than the atrophic endometrium (p < 0.05). The immunoreactivity with MMP-9 increased gradually from secretory to hyperplastic endometrium and serous carcinoma (p < 0.05). MMP-9 expression in all types of cancers except grade 1 endometrioid and clear cell compared to proliferative endometrium was significantly higher (p < 0.05) and increased from proliferative to grade 2 endometrioid, grade 3 endometrioid, serous and undifferentiated endometrial carcinoma. CONCLUSION: Gradual increments in MMP-9 expression and basement membrane laminin-1 discontinuity may indicate progression from normal to hyperplastic and to low- and high-grade cancerous endometrium.
format Online
Article
Text
id pubmed-10388054
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Scientific and Technological Research Council of Turkey (TUBITAK)
record_format MEDLINE/PubMed
spelling pubmed-103880542023-08-01 Expression of laminin-1 and matrix metalloproteinase-9 in benign and malignant endometrium KÜÇÜKAYDIN, Zehra BAŞARAN, Mustafa ÜNLÜ, Yaşar BAŞARAN, Ahmet KURDOĞLU, Mertihan Turk J Med Sci Research Article BACKGROUND/AIM: Laminin-1 and matrix metalloproteinase (MMP)-9 may play roles in the progression from benign to malignant endometrium, so we aimed to investigate their levels of expression in these tissues. MATERIALS AND METHODS: This case-control study was conducted at a tertiary care center between January 2014 and December 2016. Paraffin blocks of 50 specimens of benign endometrium with proliferative (n = 20), secretory (n = 11), and atrophic (n = 5) endometrium; simple endometrial hyperplasia without atypia (n = 12); and endometrial polyp (n = 2) histology and 49 specimens of malignant endometrium with endometrioid (n = 40), serous (n = 7), clear cell (n = 1), and undifferentiated (n = 1) types were immunostained with laminin-1 and MMP-9 antibodies and assessed for basement membrane continuity for laminin-1 and the percentage and intensity of MMP-9 expression in epithelial cytoplasm. RESULTS: Laminin-1 continuity in the basement membrane was higher in benign (92%) compared to malignant (16.3%) endometrium (p < 0.0001) without any difference between the subgroups within each group (p > 0.05). All atrophic endometria and endometrial polyps and 23.5% of low grade endometrioid and none of the other endometrial cancers showed uninterrupted basement membrane staining with laminin-1. All cases in malignant endometrium expressed MMP-9 with either low or high immunoreactivity while none of the cases in benign endometrium showed a high staining with MMP-9 (p < 0.01). Proliferative and hyperplastic endometrium together with grade 1 endometrioid cancer expressed MMP-9 better than the atrophic endometrium (p < 0.05). The immunoreactivity with MMP-9 increased gradually from secretory to hyperplastic endometrium and serous carcinoma (p < 0.05). MMP-9 expression in all types of cancers except grade 1 endometrioid and clear cell compared to proliferative endometrium was significantly higher (p < 0.05) and increased from proliferative to grade 2 endometrioid, grade 3 endometrioid, serous and undifferentiated endometrial carcinoma. CONCLUSION: Gradual increments in MMP-9 expression and basement membrane laminin-1 discontinuity may indicate progression from normal to hyperplastic and to low- and high-grade cancerous endometrium. Scientific and Technological Research Council of Turkey (TUBITAK) 2022-11-30 /pmc/articles/PMC10388054/ /pubmed/36945954 http://dx.doi.org/10.55730/1300-0144.5568 Text en © TÜBİTAK https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License.
spellingShingle Research Article
KÜÇÜKAYDIN, Zehra
BAŞARAN, Mustafa
ÜNLÜ, Yaşar
BAŞARAN, Ahmet
KURDOĞLU, Mertihan
Expression of laminin-1 and matrix metalloproteinase-9 in benign and malignant endometrium
title Expression of laminin-1 and matrix metalloproteinase-9 in benign and malignant endometrium
title_full Expression of laminin-1 and matrix metalloproteinase-9 in benign and malignant endometrium
title_fullStr Expression of laminin-1 and matrix metalloproteinase-9 in benign and malignant endometrium
title_full_unstemmed Expression of laminin-1 and matrix metalloproteinase-9 in benign and malignant endometrium
title_short Expression of laminin-1 and matrix metalloproteinase-9 in benign and malignant endometrium
title_sort expression of laminin-1 and matrix metalloproteinase-9 in benign and malignant endometrium
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388054/
https://www.ncbi.nlm.nih.gov/pubmed/36945954
http://dx.doi.org/10.55730/1300-0144.5568
work_keys_str_mv AT kucukaydinzehra expressionoflaminin1andmatrixmetalloproteinase9inbenignandmalignantendometrium
AT basaranmustafa expressionoflaminin1andmatrixmetalloproteinase9inbenignandmalignantendometrium
AT unluyasar expressionoflaminin1andmatrixmetalloproteinase9inbenignandmalignantendometrium
AT basaranahmet expressionoflaminin1andmatrixmetalloproteinase9inbenignandmalignantendometrium
AT kurdoglumertihan expressionoflaminin1andmatrixmetalloproteinase9inbenignandmalignantendometrium